Final Remarks and Thank-You
Ticiana Leal, MD, discusses how emerging targeted therapies for extensive-stage small cell lung cancer (ES-SCLC) are showing promising objective clinical outcomes that may surpass those of second-line treatments such as topotecan and CAV regimens, particularly highlighting the need to evaluate specific compounds based on platinum-sensitive vs platinum-resistant disease profiles and the potential role of TIGIT inhibitors in future treatment lines.
Video content above is prompted by the following:
- Thus far, how do the objective clinical outcomes from emerging, targeted therapies for ES-SCLC compare with second-line topotecan and CAV regimens in subsequent lines of treatment?
- With respect to platinum-sensitive vs platinum-resistant disease, which compounds in development exhibit the most potential as later lines of therapy in these 2 ES-SCLC subgroups?
- Do you envision clinical applicability of IO therapy with a T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitor for SCLC?
- Prior to its adoption as a therapeutic option, what clinical trials data must confirm its safety and efficacy as
- Monotherapy
- Combination therapy
- Importantly, in what treatment line?
- Given the objective response and progression-free survival rates reported in the Phase 2 CITYSCAPE trials, does tiragolumab co-administered with a PD-L1 inhibitor suggest its more likely role in the treatment of chemotherapy-naive, PD-L1-positive, recurrent, or metastatic non–small cell lung cancer than in ES-SCLC?
- Prior to its adoption as a therapeutic option, what clinical trials data must confirm its safety and efficacy as
Recent Videos
Related Content
